BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BC Extra | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

Myovant shares more than doubled in value Tuesday after the company revealed Phase III data showing its oral GnRH receptor antagonist relugolix led to sustained testosterone suppression in 96.7% of prostate cancer patients in Phase...
BioCentury | Jun 29, 2019

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | May 14, 2019
Company News

May 14 Company Quick Takes: F-star rejiggers Merck KGaA deal; plus Roche/Spark, AbbVie/Boehringer, Ipsen

F-star to keep lead bispecific in new deal with Merck KGaA   F-star Biotechnology Ltd. (Cambridge, U.K.) reconfigured its 2017 bispecific antibody deal with Merck KGaA (Xetra:MRK) and will now retain rights to lead candidate...
BioCentury | Apr 6, 2019

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Week In Review | Mar 29, 2019
Company News

FDA approves Clarus' oral testosterone replacement therapy

Clarus said FDA approved Jatenzo testosterone undecanoate for testosterone replacement therapy in adult males for primary hypogonadism and hypogonadotropic hypogonadism, which are conditions associated with a deficiency or absence of endogenous testosterone. Clarus Therapeutics Inc....
BioCentury | Jan 12, 2019

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BC Week In Review | Nov 16, 2018
Clinical News

FDA approves Antares' Xyosted testosterone replacement therapy

FDA approved in October Xyosted from Antares Pharma Inc. (NASDAQ:ATRS) as a testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Antares expects launch the drug by...
BC Week In Review | Aug 17, 2018
Company News

Perrigo to separate its generics business

Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) said it plans to separate its prescription generics business to focus on its consumer healthcare products. The company expects the transaction -- which could include a separation to shareholders,...
BC Extra | Jun 22, 2018
Company News

FDA cracks down on missing postmarket trial

FDA determined the Perrigo Israel Pharmaceuticals Ltd. unit of Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) has failed to comply with a postmarketing trial requirement to assess the risk of major cardiovascular events (MACE) associated with...
Items per page:
1 - 10 of 915